To assess age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
Latest Information Update: 27 May 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
Most Recent Events
- 27 May 2020 New trial record
- 01 May 2020 Results published in the Cancer Immunology Immunotherapy